0000899243-22-003924.txt : 20220201
0000899243-22-003924.hdr.sgml : 20220201
20220201201500
ACCESSION NUMBER: 0000899243-22-003924
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220128
FILED AS OF DATE: 20220201
DATE AS OF CHANGE: 20220201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRAINGER DAVID J
CENTRAL INDEX KEY: 0001887115
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40445
FILM NUMBER: 22581030
MAIL ADDRESS:
STREET 1: C/O CENTESSA PHARMACEUTICALS PLC
STREET 2: 3RD FL., 1 ASHLEY RD, ALTRINCHAM
CITY: CHESHIRE
STATE: X0
ZIP: WA14 2DT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc
CENTRAL INDEX KEY: 0001847903
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3RD FLOOR
STREET 2: 1 ASHLEY ROAD
CITY: ALTRINCHAM, CHESHIRE
STATE: X0
ZIP: WA14 2DT
BUSINESS PHONE: 44 7391 789784
MAIL ADDRESS:
STREET 1: 3RD FLOOR
STREET 2: 1 ASHLEY ROAD
CITY: ALTRINCHAM, CHESHIRE
STATE: X0
ZIP: WA14 2DT
FORMER COMPANY:
FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd
DATE OF NAME CHANGE: 20210224
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-28
0
0001847903
Centessa Pharmaceuticals plc
CNTA
0001887115
GRAINGER DAVID J
C/O CENTESSA PHARMACEUTICALS PLC
3RD FL., 1 ASHLEY RD, ALTRINCHAM
CHESHIRE
X0
WA14 2DT
UNITED KINGDOM
0
1
0
0
Chief Innovation Officer
Ordinary Shares
2022-01-28
4
P
0
27500
9.0456
A
27500
I
See footnote
Ordinary Shares
813756
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
/s/ Marella Thorell, attorney-in-fact
2022-02-01